Baxter International (BAX)
(Delayed Data from NYSE)
$36.91 USD
-1.06 (-2.79%)
Updated Oct 1, 2024 04:00 PM ET
Pre-Market: $36.91 0.00 (0.00%) 8:06 AM ET
2-Buy of 5 2
A Value F Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$36.91 USD
-1.06 (-2.79%)
Updated Oct 1, 2024 04:00 PM ET
Pre-Market: $36.91 0.00 (0.00%) 8:06 AM ET
2-Buy of 5 2
A Value F Growth B Momentum C VGM
Zacks News
Medtronic (MDT) Earns Dow Jones Sustainability Recognition
by Zacks Equity Research
Medtronic's (MDT) strong ESG practices facilitate inclusion in the North American Dow Jones Sustainability Index.
BioSig Technologies-Mayo Clinic Ink Electrophysiology Deal
by Zacks Equity Research
This collaboration is expected to bolster BioSig's (BSGM) commitment toward offering higher quality patient care by introducing innovative technological solutions to medicine.
Walgreens' Retail Pharmacy Stays Firm Amid Reimbursement Woes
by Zacks Equity Research
Walgreens' (WBA) Retail Pharmacy USA division is witnessing comparable prescription growth and also gaining traction from a solid retail prescription market.
BAX or BSX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
BAX vs. BSX: Which Stock Is the Better Value Option?
CryoLife Enters Agreement With Endospan for Aortic Stent
by Zacks Equity Research
CryoLife (CRY) eyes to expand the portfolio of aortic care, with endovascular stent graft system.
Medidata (MDSO) Collaborates With Mapi Research to Boost Rave
by Zacks Equity Research
Medidata's (MDSO) latest collaboration is expected to solve major eCOA implementation struggles in the pharmaceutical industry.
Ecolab's (ECL) Nalco Water Opens Customer Experience Center
by Zacks Equity Research
Ecolab (ECL) expects Nalco's water technologies to reduce freshwater usage by 20%.
Here's Why You Should Hold on to Ecolab (ECL) Stock Now
by Zacks Equity Research
Ecolab (ECL) continues to gain from robust product portfolio and strong international presence. However, forex remains a woe.
5 High-Flying Stocks Near 52-Week High That Can Scale Higher
by Zacks Equity Research
Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.
Bruker (BRKR) Introduces the nanoIR3-s Broadband System
by Zacks Equity Research
The launch of the FTIR spectroscopy system complements Bruker's (BRKR) target to boost its portfolio of nanoIR products.
Integra Buys Rebound Therapeutics to Boost Neurosurgery Line
by Zacks Equity Research
Integra (IART) believes, Rebound's MIS technological arm will widen its neurosurgical pipeline within Codman Specialty Surgical space.
Baxter's (BAX) Cheetah Acquisition to Aid Patient Monitoring
by Zacks Equity Research
Baxter (BAX) expects this deal to remain neutral to its earnings in 2019 and 2020.
GNC Holdings Rides on New Pacts Amid Weak Same Store Sales
by Zacks Equity Research
GNC Holdings' (GNC) recent joint venture with vitamins and nutritional supplement manufacturer International Vitamin Corporation shows high prospects at present.
Medtronic's (MDT) MiniMed 670G Gains German Reimbursement
by Zacks Equity Research
Medtronic's (MDT) MiniMed 670G is witnessing a solid uptake in the United States ever since its launch last year.
Medtronic's (MDT) IN.PACT AV Access Study Results Bode Well
by Zacks Equity Research
The results of the study will prove to be a major stride for Medtronic (MDT) to treat patient suffering from renal diseases.
Here's Why You Should Invest in Intuitive Surgical (ISRG) Now
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to benefit from da Vinci surgical system, strong global foothold and solid recurring revenue base.
Masimo (MASI) Boosts O3 Platform With Three New Indices
by Zacks Equity Research
Masimo (MASI) announced the development of three additional indices for O3 Regional Oximetry, thereby improving the O3 platform.
Zimmer Biomet (ZBH) Launches Persona Revision for Knee Care
by Zacks Equity Research
Zimmer Biomet (ZBH) prepares for the commercial launch of improvised knee replacement procedures through its flagship program, Persona Revision Knee System.
Illumina Banks on New Product Suite Despite Margin Woes
by Zacks Equity Research
The unveiling of Veriseq NIPT v2 and Illumina's (ILMN) alliance with AnchorDx in the second quarter further raise investor confidence in the stock.
Abbott (ABT) Launches Pivotal Trial TRILUMINATE in the US
by Zacks Equity Research
Given the lack of an alternative therapy to replace tricuspid regurgitation surgery, Abbott (ABT) should be at an advantage in this space.
Aurora Cannabis (ACB) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Cannabis revenue growth and improved gross margin are likely to aid Aurora Cannabis (ACB) in Q4 earnings.
Here's Why You Should Retain NextGen Healthcare Stock Now
by Zacks Equity Research
NextGen Healthcare (NXGN) is gaining traction from the U.S. RCM market and the growing EHR market. However, margin pressure remains a concern.
Edwards Lifesciences Hits a 52-Week High on Solid Prospects
by Zacks Equity Research
Edwards Lifesciences (EW) gains from recent impressive developments.
LivaNova's (LIVN) Study to Evaluate VNS Therapy Gets CMS Nod
by Zacks Equity Research
LivaNova (LIVN) is aiming to reach out to more patients, with improved enrollment program.
Here's Why You Should Invest in Amedisys (AMED) Right Now
by Zacks Equity Research
Amedisys (AMED) is currently enjoying investors' confidence, thanks to solid prospects.